Debt-to-equity of Immix Biopharma, Inc. from 30 Sep 2022 to 31 Dec 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Immix Biopharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2022 to 31 Dec 2024.
  • Immix Biopharma, Inc. Debt-to-equity for the quarter ending 31 Dec 2024 was 35%, a 106% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Immix Biopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2024 35% +18% +106% 31 Dec 2024
Q3 2024 27% +12% +84% 30 Sep 2024
Q2 2024 21% +9.3% +81% 30 Jun 2024
Q1 2024 20% +12% +150% 31 Mar 2024
Q4 2023 17% +12% +208% 31 Dec 2023
Q3 2023 15% +12% +382% 30 Sep 2023
Q2 2023 11% 30 Jun 2023
Q1 2023 8.1% 31 Mar 2023
Q4 2022 5.5% 31 Dec 2022
Q3 2022 3% 30 Sep 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.